Alpha Tau Medical Ltd. has made a significant announcement regarding its stock market presence. The company revealed that its ordinary shares will be included in the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange (TASE), effective November 5, 2026. This inclusion is expected to enhance Alpha Tau's visibility among investors and increase trading liquidity, particularly in the Israeli market.

Founded in 2016, Alpha Tau Medical is an Israeli oncology therapeutics company focused on developing innovative cancer treatments. Its primary product, Alpha DaRT, is designed for the treatment of solid tumors through a unique alpha-radiation therapy. The company is listed on both the Nasdaq and TASE under the tickers DRTS and DRTSW, respectively.

In its recent filing, Alpha Tau stated, "On October 29, 2026, Alpha Tau Medical Ltd. issued a press release titled 'Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange.'" This filing highlights the importance of the announcement for the company and its future growth prospects.

The inclusion in these indices is particularly noteworthy as the TA-125 index is considered a benchmark for the TASE, tracking the 125 largest companies on the exchange. Uzi Sofer, CEO of Alpha Tau, expressed optimism about this development, stating, "Joining the TA-90 and TA-125 indices within months of our dual listing will place us in good company among the leading companies traded on the Tel Aviv Stock Exchange. We believe inclusion will further raise our visibility with Israeli institutional investors, broaden our local shareholder base and increase trading in Tel Aviv." This sentiment reflects the potential benefits for Alpha Tau as it seeks to expand its reach and impact in the oncology field.

Alpha Tau's dual listing on the Nasdaq and TASE since August 2026 allows investors to trade its shares in both U.S. and Israeli currencies, enhancing accessibility. The company is now one of only three biomed companies in the TA-125 index, which could further attract institutional investment.

As Alpha Tau prepares for its inclusion in the TA-90 and TA-125 indices, the company is poised for increased visibility and potential growth in its shareholder base. The filing does not specify what happens next, but the market will be watching closely as the effective date approaches.